Laroprovstat lowered LDL on rosuvastatin over 28 days in a phase 1 study. Safety was the primary objective; cardiovascular benefit and long-term safety remain unproven.
Browsing: Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
LIBerate-HoFH found variable LDL responses and did not establish lerodalcibep noninferiority to evolocumab at its prespecified margin. Read the PICO appraisal.
BaxHTN found placebo-corrected systolic reductions of 8.7 and 9.8 mm Hg at 12 weeks. Review potassium events and why this differs from Bax24.
TANDEM tested obicetrapib plus ezetimibe against placebo and each component over 84 days. Review LDL effects, adverse events and the outcomes limitation.
Bax24 found a 14.0 mm Hg placebo-corrected reduction in 24-hour systolic pressure at 12 weeks. Review the primary endpoint and hyperkalaemia signal.
In CHIRACIC, adrenalectomy improved home-blood-pressure normotension with less medication versus conservative management in unilateral mild autonomous cortisol secretion-associated hypertension.
In CKD with type 2 diabetes and albuminuria, simultaneous finerenone plus empagliflozin reduced UACR more than either treatment alone at 180 days, without unexpected safety findings.
In high-risk type 2 diabetes, once-daily oral semaglutide 14 mg cut major adverse cardiovascular events versus placebo in the SOUL trial, with no kidney benefit shown. PICO summary and expert commentary.
A post-hoc ACCORD-BP analysis of 307 patients with type 2 diabetes and prior stroke links intensive SBP control below 120 mmHg to lower MACE risk. PICO summary and expert commentary.
An EXSCEL post hoc simulation and mediation analysis showing conventional risk-factor changes explain only a modest share of once-weekly exenatide’s cardiovascular effects. PICO summary and expert commentary.